Back to Insights

Blue Matter “Breakfast Club” Meeting #5: Practical Implications of the COVID-19 Crisis for Biopharma

Posted by Blue Matter on July 28th, 2020.

The Blue Matter Breakfast Club is an ongoing series of discussion forums (now virtual due to COVID-19), hosted by our team in Europe.  These forums are by invitation, bringing together leading executives from biopharma companies and other organizations to discuss critical business issues.

The fifth Breakfast Club meeting took place on 8th July 2020.  The guest speakers were:

  • Nicola Heffron, Head of Europe, bluebird bio
  • Emanuele Ostuni, Head of Europe, Cell and Gene Therapy, Novartis Oncology
  • Carsten Thiel, President, Europe, EUSA Pharma

The session was entitled Practical Implications of the COVID-19 Crisis: Ensuring Continuous Patient Drug Supply and Customer Engagement.  It included a panel discussion and several breakout sessions.  The participants discussed the impact of COVID-19 on patients, drug manufacturing and supply, sales forces and their interactions with customers, office-based personnel with biopharma companies, and more.

You can access a summary of the session here:  Breakfast Club Meeting “Bottom Line” #5